TY - JOUR
T1 - Differential expression of glucocorticoid receptor transcripts in major depressive disorder is not epigenetically programmed
AU - Alt, Simone R.
AU - Turner, Jonathan D.
AU - Klok, Melanie D.
AU - Meijer, Onno C.
AU - Lakke, Egbert A.J.F.
AU - DeRijk, Roel H.
AU - Muller, Claude P.
N1 - Funding Information:
This study was supported by the International Research Training Group (DFG Grant GRK 1389/1) and a FNR grant (FNR07-043) to SRA and CPM and a NARSAD IIA grant to OCM. MDK and RHdR were supported by the KNAW and a grant from the Kassenaar fund. Further funding was provided by the Ministry of Culture, Higher Education and Research (MCESR), Luxembourg and the Ministry of Health, Luxembourg. The DFG, NARSAD, KNAW, Kassenar fund and MCESR provided no further input into the study design, analysis, interpretation, or decision to publish the accompanying manuscript.
PY - 2010/5
Y1 - 2010/5
N2 - Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is one of the most consistent findings in major depressive disorder (MDD). Impaired HPA feedback may be due to the lower glucocorticoid receptor (GR) or mineralocorticoid receptor (MR) levels in the forebrain. GR levels are transcriptionally controlled by multiple untranslated alternative first exons, each with its own promoter providing a mechanism for tissue-specific fine-tuning of GR levels. Recently epigenetic methylation of these GR promoters was shown to modulate hippocampal GR levels. Here we investigate in post-mortem brain tissues whether in MDD HPA axis hyperactivity may be due to epigenetic modulation of GR transcript variants.Levels of GRα, GRβ and GR-P transcripts were homogeneous throughout the limbic system, with GRα being the most abundant (83%), followed by GR-P (5-6%) while GRβ was barely detectable (0.02%). Among the alternative first exons, 1B and 1C were the most active, while 1E and 1J showed the lowest expression and transcript 1F expressed intermediate levels of about 1%.In MDD, total GR levels were unaltered, although GRα was decreased in the amygdala and cingulate gyrus (p<0.05); transcripts containing exons 1B, 1C and 1F were lower, and 1D and1J were increased in some regions. NGFI-A, a transcription factor of exon 1F was down-regulated in the hippocampus of MDD patients; concomitantly exon 1F expression was reduced. Bisulphite sequencing of the alternative promoters showed low methylation levels in both MDD and control brains. Promoter 1F was uniformly unmethylated, suggesting that reduced 1F transcript levels are not linked to promoter methylation but to the observed dearth of NGFI-A.Previous studies showed high methylation levels in the 1F promoter, associated with childhood abuse. Provided our donors were not abused, our results suggest that the pathomechanism of MDD is similar but nevertheless distinct from that of abuse victims, explaining the clinical similarity of both conditions and that susceptibility to depression may be either predisposed by early trauma or developed independent of such a condition. However, this should be further confirmed in dedicated studies in larger cohorts.
AB - Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is one of the most consistent findings in major depressive disorder (MDD). Impaired HPA feedback may be due to the lower glucocorticoid receptor (GR) or mineralocorticoid receptor (MR) levels in the forebrain. GR levels are transcriptionally controlled by multiple untranslated alternative first exons, each with its own promoter providing a mechanism for tissue-specific fine-tuning of GR levels. Recently epigenetic methylation of these GR promoters was shown to modulate hippocampal GR levels. Here we investigate in post-mortem brain tissues whether in MDD HPA axis hyperactivity may be due to epigenetic modulation of GR transcript variants.Levels of GRα, GRβ and GR-P transcripts were homogeneous throughout the limbic system, with GRα being the most abundant (83%), followed by GR-P (5-6%) while GRβ was barely detectable (0.02%). Among the alternative first exons, 1B and 1C were the most active, while 1E and 1J showed the lowest expression and transcript 1F expressed intermediate levels of about 1%.In MDD, total GR levels were unaltered, although GRα was decreased in the amygdala and cingulate gyrus (p<0.05); transcripts containing exons 1B, 1C and 1F were lower, and 1D and1J were increased in some regions. NGFI-A, a transcription factor of exon 1F was down-regulated in the hippocampus of MDD patients; concomitantly exon 1F expression was reduced. Bisulphite sequencing of the alternative promoters showed low methylation levels in both MDD and control brains. Promoter 1F was uniformly unmethylated, suggesting that reduced 1F transcript levels are not linked to promoter methylation but to the observed dearth of NGFI-A.Previous studies showed high methylation levels in the 1F promoter, associated with childhood abuse. Provided our donors were not abused, our results suggest that the pathomechanism of MDD is similar but nevertheless distinct from that of abuse victims, explaining the clinical similarity of both conditions and that susceptibility to depression may be either predisposed by early trauma or developed independent of such a condition. However, this should be further confirmed in dedicated studies in larger cohorts.
KW - Alternative transcripts
KW - Epigenetics
KW - Glucocorticoid receptor
KW - MRNA expression
KW - Major depressive disorder
KW - Pyrosequencing
UR - http://www.scopus.com/inward/record.url?scp=77950689477&partnerID=8YFLogxK
U2 - 10.1016/j.psyneuen.2009.09.001
DO - 10.1016/j.psyneuen.2009.09.001
M3 - Article
C2 - 19782477
AN - SCOPUS:77950689477
SN - 0306-4530
VL - 35
SP - 544
EP - 556
JO - Psychoneuroendocrinology
JF - Psychoneuroendocrinology
IS - 4
ER -